Fuchs Endothelial Corneal Dystrophy

Complex MONDO:0005321 Pathograph 18 Corneal endothelial dystrophy Posterior corneal dystrophy Hereditary disease

Fuchs endothelial corneal dystrophy is an adult-onset posterior corneal dystrophy in which progressive corneal endothelial dysfunction and cell loss produce Descemet membrane guttae, corneal edema, corneal opacity, and declining visual acuity. Familial and population-risk forms involve multiple genes and loci, with an intronic TCF4 CTG repeat expansion being the most common genetic association in late-onset disease and rarer disease-causing variants reported in COL8A2, SLC4A11, ZEB1, and AGBL1.

Ask OpenScientist

Ask a research question about Fuchs Endothelial Corneal Dystrophy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
10
Pathophys.
9
Phenotypes
18
Pathograph
5
Genes
2
Treatments
2
Subtypes
2
Trials
14
References
1
Deep Research
👪

Inheritance

2
Autosomal dominant inheritance HP:0000006
autosomal dominant inheritance
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"Autosomal dominant"
Orphanet records autosomal dominant inheritance for FECD.
Multigenic or multifactorial inheritance
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"Multigenic/multifactorial"
Orphanet also records a multigenic/multifactorial inheritance category, consistent with common late-onset FECD risk architecture.
◆

Subtypes

2
Early-onset Fuchs endothelial corneal dystrophy
Rare early-onset FECD, described in corneal-dystrophy classification as beginning in the first decade of life and commonly associated with COL8A2 variants.
Show evidence (1 reference)
PMID:34130750 SUPPORT Human Clinical
"The most recent International Classification of Corneal Dystrophies categorizes FECD into two types: 1) rare early-onset FECD, and 2) more common late-onset FECD."
The review summarizes the current classification into early-onset and late-onset FECD.
Late-onset Fuchs endothelial corneal dystrophy
Common late-onset FECD that usually manifests in mid-adulthood and is often associated with TCF4 repeat-expansion risk architecture.
Show evidence (1 reference)
PMID:34130750 SUPPORT Human Clinical
"On average, late-onset FECD manifests in the fifth decade of life"
The review supports fifth-decade onset as characteristic of the common late-onset form.
⚙

Pathophysiology

10
TCF4 CTG Repeat Expansion Susceptibility
An intronic CTG repeat expansion in TCF4 is the strongest common genetic association with late-onset FECD and is found in many affected patients.
TCF4 link
corneal endothelium link
Downstream
Toxic CUG RNA Foci Expanded TCF4 transcripts produce toxic CUG-repeat RNA foci in corneal endothelial cells.
Show evidence (1 reference)
PMID:25593321 SUPPORT Human Clinical
"Among the several genes and loci associated with FECD, the strongest association is with an intronic (CTG·CAG)n trinucleotide repeat expansion in the TCF4 gene, which is found in the majority of affected patients."
This human corneal-endothelium study identifies the TCF4 repeat expansion as the strongest common genetic association in FECD.
Toxic CUG RNA Foci
Expanded TCF4 repeat transcripts accumulate as CUG-repeat RNA foci in FECD corneal endothelial cells and sequester the splicing regulator MBNL1.
corneal endothelial cell link
RNA splicing factor sequestration link ⚠ ABNORMAL
corneal endothelium link
Downstream
Widespread Endothelial mRNA Missplicing MBNL1 sequestration disrupts normal splicing of MBNL1-regulated transcripts.
Show evidence (2 references)
PMID:25593321 SUPPORT Human Clinical
"Corneal endothelial cells from FECD patients harbor a poly(CUG)n RNA that can be visualized as RNA foci containing this condensed RNA and associated proteins."
This directly supports toxic CUG-repeat RNA foci in FECD corneal endothelial cells.
PMID:25593321 SUPPORT Human Clinical
"the poly(CUG)n RNA co-localizes with and sequesters the mRNA-splicing factor MBNL1, leading to missplicing of essential MBNL1-regulated mRNAs."
This links CUG-repeat foci to MBNL1 sequestration and downstream missplicing.
Widespread Endothelial mRNA Missplicing
FECD corneal endothelial tissue carrying the TCF4 CTG repeat expansion has widespread mRNA splicing changes, including changes in pathways relevant to endothelial barrier function.
corneal endothelial cell link
mRNA missplicing link ⚠ ABNORMAL
corneal endothelium link
Downstream
Corneal Endothelial Barrier Dysfunction Missplicing affects endothelial barrier-function biology.
Show evidence (2 references)
PMID:28118661 SUPPORT Human Clinical
"Corneal endothelial tissue from FECD patients containing a CTG TNR expansion sequence in the TCF4 gene revealed widespread changes in mRNA splicing, including a novel splicing event involving FGFR2."
This supports widespread missplicing in FECD corneal endothelial tissue with TCF4 repeat expansion.
PMID:28118661 SUPPORT Human Clinical
"Changes to the endothelial barrier function, a known event in the development of FECD, was identified as a key biological process influenced by the missplicing"
This connects missplicing to endothelial barrier dysfunction in FECD.
Corneal Endothelial Barrier Dysfunction
The corneal endothelium normally keeps the cornea clear by pump and barrier activity that maintains stromal deturgescence; FECD disrupts this function, allowing stromal hydration and edema.
corneal endothelial cell link
corneal endothelium link
Downstream
Corneal Edema Loss of endothelial deturgescence increases corneal hydration and edema.
Show evidence (2 references)
PMID:25593321 SUPPORT Human Clinical
"The corneal endothelium is a non-regenerative cell monolayer on the internal surface of the cornea and is responsible for the maintenance of corneal clarity by continual deturgescence of the collagenous corneal stroma."
This defines the corneal endothelial function that is lost as FECD progresses.
PMID:34130750 SUPPORT Human Clinical
"The cornea's ability to maintain stromal dehydration is impaired, causing painful epithelial bullae and loss of vision"
This directly links impaired corneal dehydration to painful bullae and vision loss in FECD.
ER Stress and Unfolded Protein Response Activation
FECD corneal endothelial cells show activation of endoplasmic-reticulum stress and unfolded-protein-response pathways, including IRE1, PERK, GRP78, and CHOP activation.
corneal endothelial cell link
response to endoplasmic reticulum stress link ↑ INCREASED response to unfolded protein link ↑ INCREASED
corneal endothelium link
Downstream
Corneal Endothelial Apoptosis Prolonged ER stress and CHOP activation promote apoptotic signaling in FECD corneal endothelial cells.
Show evidence (2 references)
PMID:28727885 SUPPORT Human Clinical
"The unfolded protein response (UPR) is believed to play a role in the pathogenesis of Fuchs' endothelial corneal dystrophy (FECD)."
This supports UPR involvement in FECD pathogenesis.
PMID:28727885 SUPPORT In Vitro
"GRP78, phosphorylated IRE1, PERK, and CHOP showed higher activation in iFECD than in iHCEC."
The experimental FECD cell model showed increased ER-stress and UPR markers.
Oxidative and Mitochondrial Stress
FECD corneal endothelial cells experience oxidative stress, mitochondrial dysfunction, and impaired mitochondrial quality-control pathways that reduce endothelial-cell viability and can converge on apoptosis.
corneal endothelial cell link
response to oxidative stress link ↑ INCREASED mitochondrial quality-control dysfunction link ⚠ ABNORMAL mitochondrion organization link ⚠ ABNORMAL
corneal endothelium link
Downstream
TGF-beta-Driven Endothelial-Mesenchymal Transition Oxidative stress can induce endothelial-mesenchymal transition in FECD corneal endothelial cells.
Corneal Endothelial Apoptosis Oxidative and mitochondrial stress increase vulnerability of corneal endothelial cells to apoptosis.
Show evidence (3 references)
PMID:26937169 SUPPORT Human Clinical
"Impairment of endothelial barrier and pump function and cell death from oxidative and unfolded protein stress contribute to disease progression."
This FECD clinical review directly supports oxidative stress as a contributor to disease progression.
PMID:33724294 SUPPORT Human Clinical
"Furthermore, this article reviews investigations of ocular diseases with impaired mitophagy, including Fuchs endothelial corneal dystrophy, primary open-angle glaucoma, diabetic retinopathy, and age-related macular degeneration"
This review includes FECD among ocular diseases with impaired mitophagy.
PMID:33724294 SUPPORT Other
"mitochondria provide energy through the generation of adenosine triphosphate (ATP), regulate cellular metabolism, provide redox balancing, participate in immune signaling, and can initiate apoptosis."
This supports the mechanistic bridge from mitochondrial dysfunction to apoptosis.
TGF-beta-Driven Endothelial-Mesenchymal Transition
TGF-beta signaling in FECD corneal endothelial cells up-regulates EMT-related transcriptional regulators including ZEB1 and SNAI1, promoting endothelial-mesenchymal transition and extracellular-matrix deposition.
corneal endothelial cell link
ZEB1 link
endothelial-mesenchymal transition link ↑ INCREASED
corneal endothelium link
Downstream
Descemet Membrane Guttae EMT-associated extracellular-matrix deposition contributes to Descemet membrane guttae and thickening.
Show evidence (2 references)
PMID:34130750 SUPPORT Human Clinical
"The up-regulation of EMT-related genes ZEB1 and SNAI1 by TGF-β in CECs in FECD patients was associated with the deposition of ECM proteins"
This directly supports TGF-beta-driven EMT gene up-regulation and ECM deposition in FECD corneal endothelial cells.
PMID:34130750 SUPPORT In Vitro
"A study using an in vitro model of FECD provided the first evidence that oxidative stress induced by MN resulted in EMT, leading to increased expression of SNAI1, ZEB1, fibronectin and N-cadherin in CECs"
This in vitro FECD-model evidence supports oxidative-stress induction of EMT in corneal endothelial cells.
Corneal Endothelial Apoptosis
Sustained UPR/ER-stress signaling activates apoptotic pathways in FECD corneal endothelial cells and contributes to progressive cell loss.
corneal endothelial cell link
apoptotic process link ↑ INCREASED
corneal endothelium link
Downstream
Endothelial Cell Depletion Apoptosis contributes to loss of corneal endothelial cells.
Show evidence (2 references)
PMID:28727885 SUPPORT In Vitro
"Knockdown of CHOP attenuated the ER stress-induced cleavage of caspase-9, which is caused by intrinsic pathway activation."
This supports ER-stress-linked apoptotic signaling in FECD-derived corneal endothelial cells.
PMID:34130750 SUPPORT Human Clinical
"The molecular mechanisms associated with Fuchs endothelial corneal dystrophy, such as endoplasmic reticulum stress and unfolded protein response pathway, oxidative stress, mitochondrial dysregulation pathway, apoptosis pathway, mitophagy, epithelial-mesenchymal transition pathway, RNA toxicity..."
The review identifies apoptosis among reported FECD molecular mechanisms.
Descemet Membrane Guttae
FECD produces extracellular excrescences called guttae on a thickened Descemet membrane, creating the characteristic posterior corneal dystrophy morphology.
extracellular matrix organization link ⚠ ABNORMAL
cornea link
Downstream
Descemet Membrane Abnormality Guttae and thickening are the morphologic basis of abnormal Descemet membrane morphology.
Corneal Opacity Guttae and edema reduce posterior corneal optical quality.
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"excrescences on a thickened Descemet membrane (corneal guttae)"
Orphanet defines FECD by corneal guttae on a thickened Descemet membrane.
PMID:34130750 SUPPORT Human Clinical
"Its main clinical signs are an accelerated decrease in the number of endothelial cells, thickening of Descemet's membrane and formation of guttae in the extracellular matrix."
This review identifies endothelial-cell loss, Descemet membrane thickening, and guttae as principal FECD signs.
Endothelial Cell Depletion
Progressive reduction in corneal endothelial cell number lowers endothelial reserve and contributes to corneal edema and loss of transparency.
corneal endothelial cell link
corneal endothelium link
Downstream
Reduced Corneal Endothelial Cell Count Clinical measurement shows reduced numbers of corneal endothelial cells.
Corneal Edema Reduced endothelial cell reserve impairs corneal dehydration.
Show evidence (1 reference)
PMID:34130750 SUPPORT Human Clinical
"Its main clinical signs are an accelerated decrease in the number of endothelial cells, thickening of Descemet's membrane and formation of guttae in the extracellular matrix."
This supports progressive endothelial-cell depletion as a core FECD clinical feature.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Fuchs Endothelial Corneal Dystrophy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Eye 4
Reduced Visual Acuity VERY_FREQUENT Reduced visual acuity (HP:0007663)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"HP:0007663 | Reduced visual acuity | Very frequent (99-80%)"
Orphanet lists reduced visual acuity as very frequent in FECD.
ORPHA:98974 SUPPORT Other
"gradually decreased visual acuity"
Orphanet's definition explicitly includes gradual visual-acuity decline.
Corneal Opacity VERY_FREQUENT Corneal opacity (HP:0007957)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"HP:0007957 | Corneal opacity | Very frequent (99-80%)"
Orphanet lists corneal opacity as very frequent in FECD.
Visual Loss FREQUENT Visual loss (HP:0000572)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"HP:0000572 | Visual loss | Frequent (79-30%)"
Orphanet lists visual loss as frequent in FECD.
PMID:25593321 SUPPORT Human Clinical
"Advanced FECD, treatable only by corneal transplantation, is characterized by extensive guttae, endothelial cell loss, and vision loss due to stromal edema."
This human FECD study links advanced disease to vision loss due to stromal edema.
Nyctalopia FREQUENT Nyctalopia (HP:0000662)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"HP:0000662 | Nyctalopia | Frequent (79-30%)"
Orphanet lists nyctalopia as frequent in FECD.
Metabolism 1
Corneal Edema VERY_FREQUENT Edema (HP:0000969)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"HP:0000969 | Edema | Very frequent (99-80%)"
Orphanet lists edema as very frequent in FECD; the disease definition specifies corneal edema.
ORPHA:98974 SUPPORT Other
"generalized corneal edema"
Orphanet's definition localizes the edema to the cornea.
Other 4
Abnormal Corneal Endothelium Morphology VERY_FREQUENT Abnormal corneal endothelium morphology (HP:0011488)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"HP:0011488 | Abnormal corneal endothelium morphology | Very frequent (99-80%)"
Orphanet lists abnormal corneal endothelium morphology as very frequent in FECD.
Descemet Membrane Abnormality VERY_FREQUENT Abnormal Descemet membrane morphology (HP:0011490)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"HP:0011490 | Abnormal Descemet membrane morphology | Very frequent (99-80%)"
Orphanet lists abnormal Descemet membrane morphology as very frequent in FECD.
ORPHA:98974 SUPPORT Other
"thickened Descemet membrane (corneal guttae)"
Orphanet's definition specifies the Descemet membrane abnormality.
Reduced Corneal Endothelial Cell Count VERY_FREQUENT Reduced number of corneal endothelial cells (HP:0011491)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"HP:0011491 | Reduced number of corneal endothelial cells | Very frequent (99-80%)"
Orphanet lists reduced numbers of corneal endothelial cells as very frequent in FECD.
PMID:34130750 SUPPORT Human Clinical
"Its main clinical signs are an accelerated decrease in the number of endothelial cells, thickening of Descemet's membrane and formation of guttae in the extracellular matrix."
This review directly supports accelerated endothelial-cell loss as a main clinical sign.
Eye Movement-Induced Pain FREQUENT Eye movement-induced pain (HP:0030857)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"HP:0030857 | Eye movement-induced pain | Frequent (79-30%)"
Orphanet lists eye movement-induced pain as frequent in FECD.
PMID:34130750 PARTIAL Human Clinical
"The cornea's ability to maintain stromal dehydration is impaired, causing painful epithelial bullae and loss of vision"
The review supports corneal pain from epithelial bullae, though not specifically pain induced by eye movement.
🧬

Genetic Associations

5
TCF4 CTG repeat expansion and FECD susceptibility (Disease-causing germline mutation(s) in)
Show evidence (2 references)
ORPHA:98974 SUPPORT Other
"TCF4 | transcription factor 4 | hgnc:11634 | Disease-causing germline mutation(s) in"
Orphanet lists TCF4 as a disease-associated gene for FECD.
PMID:25593321 SUPPORT Human Clinical
"the strongest association is with an intronic (CTG·CAG)n trinucleotide repeat expansion in the TCF4 gene"
This identifies the key TCF4 repeat-expansion association in FECD.
COL8A2 disease-associated variants (Disease-causing germline mutation(s) in)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"COL8A2 | collagen type VIII alpha 2 chain | hgnc:2216 | Disease-causing germline mutation(s) in"
Orphanet lists COL8A2 as a disease-associated gene for FECD.
SLC4A11 disease-associated variants (Disease-causing germline mutation(s) in)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"SLC4A11 | solute carrier family 4 member 11 | hgnc:16438 | Disease-causing germline mutation(s) in"
Orphanet lists SLC4A11 as a disease-associated gene for FECD.
ZEB1 loss-of-function disease-associated variants (Disease-causing germline mutation(s) in)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"ZEB1 | zinc finger E-box binding homeobox 1 | hgnc:11642 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet lists ZEB1 loss of function as disease-associated in FECD.
AGBL1 disease-associated variants (Disease-causing germline mutation(s) in)
Show evidence (1 reference)
ORPHA:98974 SUPPORT Other
"AGBL1 | AGBL carboxypeptidase 1 | hgnc:26504 | Disease-causing germline mutation(s) in"
Orphanet lists AGBL1 as a disease-associated gene for FECD.
💊

Treatments

2
Endothelial keratoplasty or corneal transplantation
Action: corneal transplantation MAXO:0010034
Endothelial keratoplasty, including DMEK or DSAEK, and corneal transplantation replace or restore endothelial function in visually significant advanced FECD.
Mechanism Target:
RESTORES Corneal Endothelial Barrier Dysfunction — Endothelial transplantation restores the endothelial deturgescence function lost in advanced FECD.
Show evidence (3 references)
PMID:25593321 SUPPORT Human Clinical
"Advanced FECD, treatable only by corneal transplantation, is characterized by extensive guttae, endothelial cell loss, and vision loss due to stromal edema."
This directly supports corneal transplantation as treatment for advanced FECD.
PMID:32735996 SUPPORT Human Clinical
"The management of end-stage FECD has been revolutionized in developed countries by the introduction of endothelial keratoplasty that can rapidly and effectively restore vision."
This review supports endothelial keratoplasty for end-stage FECD.
PMID:32965936 SUPPORT Human Clinical
"Compared to DSAEK, DMEK has better visual outcomes, faster recovery time, and lower immune rejection rate."
This supports DMEK as a modern endothelial keratoplasty option relevant to FECD transplantation care.
Topical ripasudil after DWEK or phacoemulsification
Action: Pharmacotherapy NCIT:C15986
Agent: ripasudil ↗
Topical ROCK inhibition with ripasudil has randomized clinical-trial evidence for accelerating corneal clearing after DWEK and reducing endothelial cell loss after phacoemulsification in FECD.
Mechanism Target:
MODULATES Corneal Endothelial Barrier Dysfunction — ROCK inhibition improves endothelial recovery and corneal deturgescence in selected FECD surgical contexts.
Show evidence (2 references)
PMID:42018070 SUPPORT Human Clinical
"Adjunctive topical ripasudil after DWEK accelerates endothelial recovery, corneal deturgescence, and visual rehabilitation compared with DWEK alone, without compromising safety."
This prospective randomized comparative clinical study supports adjunctive ripasudil after DWEK in mild-to-moderate FECD.
PMID:39946654 SUPPORT Human Clinical
"The topical ROCK inhibitor, or ripasudil, demonstrated beneficial effects on preventing endothelial cell loss and improving endothelial function in patients with FECD undergoing phacoemulsification."
This randomized trial supports ripasudil for endothelial protection after phacoemulsification in FECD.
🔬

Clinical Trials

2
NCT04057053 COMPLETED
Trial of netarsudil after Descemetorhexis Without Endothelial Keratoplasty to assess whether ROCK inhibition speeds corneal clearance.
Show evidence (1 reference)
clinicaltrials:NCT04057053 SUPPORT Human Clinical
"Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK."
The ClinicalTrials.gov summary directly identifies the netarsudil-after-DWEK trial objective in FECD-related corneal clearance.
NCT02653391 COMPLETED
Phase 1/2 trial evaluating topical elamipretide ophthalmic solution in people with Fuchs corneal endothelial dystrophy and mild-to-moderate corneal edema.
Show evidence (1 reference)
clinicaltrials:NCT02653391 SUPPORT Human Clinical
"This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema."
The ClinicalTrials.gov summary supports a completed elamipretide trial in FCED with mild-to-moderate corneal edema.
{ }

Source YAML

click to show 
name: Fuchs Endothelial Corneal Dystrophy
creation_date: "2026-05-11T17:36:18Z"
updated_date: "2026-05-11T17:36:18Z"
category: Complex
description: >-
  Fuchs endothelial corneal dystrophy is an adult-onset posterior corneal
  dystrophy in which progressive corneal endothelial dysfunction and cell loss
  produce Descemet membrane guttae, corneal edema, corneal opacity, and
  declining visual acuity. Familial and population-risk forms involve multiple
  genes and loci, with an intronic TCF4 CTG repeat expansion being the most
  common genetic association in late-onset disease and rarer disease-causing
  variants reported in COL8A2, SLC4A11, ZEB1, and AGBL1.
disease_term:
  preferred_term: Fuchs endothelial corneal dystrophy
  term:
    id: MONDO:0005321
    label: Fuchs' endothelial dystrophy
synonyms:
- Endoepithelial corneal dystrophy
- FECD
- Late hereditary endothelial dystrophy
parents:
- Corneal endothelial dystrophy
- Posterior corneal dystrophy
- Hereditary disease
has_subtypes:
- name: Early-onset FECD
  display_name: Early-onset Fuchs endothelial corneal dystrophy
  description: >-
    Rare early-onset FECD, described in corneal-dystrophy classification as
    beginning in the first decade of life and commonly associated with COL8A2
    variants.
  evidence:
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most recent International Classification of Corneal Dystrophies categorizes FECD into two types: 1) rare early-onset FECD, and 2) more common late-onset FECD."
    explanation: The review summarizes the current classification into early-onset and late-onset FECD.
- name: Late-onset FECD
  display_name: Late-onset Fuchs endothelial corneal dystrophy
  description: >-
    Common late-onset FECD that usually manifests in mid-adulthood and is often
    associated with TCF4 repeat-expansion risk architecture.
  evidence:
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On average, late-onset FECD manifests in the fifth decade of life"
    explanation: The review supports fifth-decade onset as characteristic of the common late-onset form.
notes: >-
  ORPHA:98974 records exact cross-references to MONDO:0005321, MeSH:D005642,
  and UMLS:C0016781, and broader OMIM cross-references to OMIM:136800,
  OMIM:610158, OMIM:613267, OMIM:613268, OMIM:613269, OMIM:613270,
  OMIM:613271, and OMIM:615523. Orphanet lists autosomal dominant,
  multigenic/multifactorial, and not-applicable inheritance categories,
  reflecting both monogenic familial forms and common complex late-onset FECD.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal dominant"
    explanation: Orphanet records autosomal dominant inheritance for FECD.
- name: Multigenic or multifactorial inheritance
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multigenic/multifactorial"
    explanation: Orphanet also records a multigenic/multifactorial inheritance category, consistent with common late-onset FECD risk architecture.
prevalence:
- population: Worldwide
  percentage: Unknown
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Unknown | Worldwide | Point prevalence | ORPHANET"
    explanation: Orphanet records worldwide point prevalence as unknown.
progression:
- phase: Adult onset
  age_range: Adulthood
  notes: >-
    Orphanet records adult onset. Late-onset disease typically progresses from
    guttae and reduced endothelial reserve to corneal edema, opacity, and
    visual decline.
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adult"
    explanation: Orphanet records adult onset for FECD.
pathophysiology:
- name: TCF4 CTG Repeat Expansion Susceptibility
  description: >-
    An intronic CTG repeat expansion in TCF4 is the strongest common genetic
    association with late-onset FECD and is found in many affected patients.
  genes:
  - preferred_term: TCF4
    term:
      id: hgnc:11634
      label: TCF4
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Toxic CUG RNA Foci
    description: Expanded TCF4 transcripts produce toxic CUG-repeat RNA foci in corneal endothelial cells.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among the several genes and loci associated with FECD, the strongest
      association is with an intronic (CTG·CAG)n trinucleotide repeat expansion
      in the TCF4 gene, which is found in the majority of affected patients.
    explanation: This human corneal-endothelium study identifies the TCF4 repeat expansion as the strongest common genetic association in FECD.
- name: Toxic CUG RNA Foci
  description: >-
    Expanded TCF4 repeat transcripts accumulate as CUG-repeat RNA foci in FECD
    corneal endothelial cells and sequester the splicing regulator MBNL1.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  biological_processes:
  - preferred_term: RNA splicing factor sequestration
    term:
      id: GO:0000398
      label: mRNA splicing, via spliceosome
    modifier: ABNORMAL
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Widespread Endothelial mRNA Missplicing
    description: MBNL1 sequestration disrupts normal splicing of MBNL1-regulated transcripts.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Corneal endothelial cells from FECD patients harbor a poly(CUG)n RNA that
      can be visualized as RNA foci containing this condensed RNA and associated
      proteins.
    explanation: This directly supports toxic CUG-repeat RNA foci in FECD corneal endothelial cells.
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the poly(CUG)n RNA co-localizes with and sequesters the mRNA-splicing
      factor MBNL1, leading to missplicing of essential MBNL1-regulated mRNAs.
    explanation: This links CUG-repeat foci to MBNL1 sequestration and downstream missplicing.
- name: Widespread Endothelial mRNA Missplicing
  description: >-
    FECD corneal endothelial tissue carrying the TCF4 CTG repeat expansion has
    widespread mRNA splicing changes, including changes in pathways relevant to
    endothelial barrier function.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  biological_processes:
  - preferred_term: mRNA missplicing
    term:
      id: GO:0000398
      label: mRNA splicing, via spliceosome
    modifier: ABNORMAL
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Corneal Endothelial Barrier Dysfunction
    description: Missplicing affects endothelial barrier-function biology.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:28118661
    reference_title: "Trinucleotide Repeat Expansion in the Transcription Factor 4 (TCF4) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Corneal endothelial tissue from FECD patients containing a CTG TNR
      expansion sequence in the TCF4 gene revealed widespread changes in mRNA
      splicing, including a novel splicing event involving FGFR2.
    explanation: This supports widespread missplicing in FECD corneal endothelial tissue with TCF4 repeat expansion.
  - reference: PMID:28118661
    reference_title: "Trinucleotide Repeat Expansion in the Transcription Factor 4 (TCF4) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Changes to the endothelial barrier function, a known event in the
      development of FECD, was identified as a key biological process influenced
      by the missplicing
    explanation: This connects missplicing to endothelial barrier dysfunction in FECD.
- name: Corneal Endothelial Barrier Dysfunction
  description: >-
    The corneal endothelium normally keeps the cornea clear by pump and barrier
    activity that maintains stromal deturgescence; FECD disrupts this function,
    allowing stromal hydration and edema.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Corneal Edema
    description: Loss of endothelial deturgescence increases corneal hydration and edema.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The corneal endothelium is a non-regenerative cell monolayer on the
      internal surface of the cornea and is responsible for the maintenance of
      corneal clarity by continual deturgescence of the collagenous corneal
      stroma.
    explanation: This defines the corneal endothelial function that is lost as FECD progresses.
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cornea's ability to maintain stromal dehydration is impaired, causing
      painful epithelial bullae and loss of vision
    explanation: This directly links impaired corneal dehydration to painful bullae and vision loss in FECD.
- name: ER Stress and Unfolded Protein Response Activation
  description: >-
    FECD corneal endothelial cells show activation of endoplasmic-reticulum
    stress and unfolded-protein-response pathways, including IRE1, PERK, GRP78,
    and CHOP activation.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  biological_processes:
  - preferred_term: response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  - preferred_term: response to unfolded protein
    term:
      id: GO:0006986
      label: response to unfolded protein
    modifier: INCREASED
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Corneal Endothelial Apoptosis
    description: Prolonged ER stress and CHOP activation promote apoptotic signaling in FECD corneal endothelial cells.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:28727885
    reference_title: "Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs' Endothelial Corneal Dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The unfolded protein response (UPR) is believed to play a role in the
      pathogenesis of Fuchs' endothelial corneal dystrophy (FECD).
    explanation: This supports UPR involvement in FECD pathogenesis.
  - reference: PMID:28727885
    reference_title: "Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs' Endothelial Corneal Dystrophy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      GRP78, phosphorylated IRE1, PERK, and CHOP showed higher activation in
      iFECD than in iHCEC.
    explanation: The experimental FECD cell model showed increased ER-stress and UPR markers.
- name: Oxidative and Mitochondrial Stress
  description: >-
    FECD corneal endothelial cells experience oxidative stress, mitochondrial
    dysfunction, and impaired mitochondrial quality-control pathways that
    reduce endothelial-cell viability and can converge on apoptosis.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: mitochondrial quality-control dysfunction
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
    modifier: ABNORMAL
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
    modifier: ABNORMAL
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: TGF-beta-Driven Endothelial-Mesenchymal Transition
    description: Oxidative stress can induce endothelial-mesenchymal transition in FECD corneal endothelial cells.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Corneal Endothelial Apoptosis
    description: Oxidative and mitochondrial stress increase vulnerability of corneal endothelial cells to apoptosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:26937169
    reference_title: "Fuchs endothelial corneal dystrophy: current perspectives."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Impairment of endothelial barrier and pump function and cell death from
      oxidative and unfolded protein stress contribute to disease progression.
    explanation: This FECD clinical review directly supports oxidative stress as a contributor to disease progression.
  - reference: PMID:33724294
    reference_title: "Mitophagy: An Emerging Target in Ocular Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Furthermore, this article reviews investigations of ocular diseases with
      impaired mitophagy, including Fuchs endothelial corneal dystrophy, primary
      open-angle glaucoma, diabetic retinopathy, and age-related macular
      degeneration
    explanation: This review includes FECD among ocular diseases with impaired mitophagy.
  - reference: PMID:33724294
    reference_title: "Mitophagy: An Emerging Target in Ocular Pathology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      mitochondria provide energy through the generation of adenosine
      triphosphate (ATP), regulate cellular metabolism, provide redox balancing,
      participate in immune signaling, and can initiate apoptosis.
    explanation: This supports the mechanistic bridge from mitochondrial dysfunction to apoptosis.
- name: TGF-beta-Driven Endothelial-Mesenchymal Transition
  description: >-
    TGF-beta signaling in FECD corneal endothelial cells up-regulates
    EMT-related transcriptional regulators including ZEB1 and SNAI1, promoting
    endothelial-mesenchymal transition and extracellular-matrix deposition.
  genes:
  - preferred_term: ZEB1
    term:
      id: hgnc:11642
      label: ZEB1
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  biological_processes:
  - preferred_term: endothelial-mesenchymal transition
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
    modifier: INCREASED
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Descemet Membrane Guttae
    description: EMT-associated extracellular-matrix deposition contributes to Descemet membrane guttae and thickening.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The up-regulation of EMT-related genes ZEB1 and SNAI1 by TGF-β in CECs in
      FECD patients was associated with the deposition of ECM proteins
    explanation: This directly supports TGF-beta-driven EMT gene up-regulation and ECM deposition in FECD corneal endothelial cells.
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      A study using an in vitro model of FECD provided the first evidence that
      oxidative stress induced by MN resulted in EMT, leading to increased
      expression of SNAI1, ZEB1, fibronectin and N-cadherin in CECs
    explanation: This in vitro FECD-model evidence supports oxidative-stress induction of EMT in corneal endothelial cells.
- name: Corneal Endothelial Apoptosis
  description: >-
    Sustained UPR/ER-stress signaling activates apoptotic pathways in FECD
    corneal endothelial cells and contributes to progressive cell loss.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Endothelial Cell Depletion
    description: Apoptosis contributes to loss of corneal endothelial cells.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:28727885
    reference_title: "Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs' Endothelial Corneal Dystrophy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Knockdown of CHOP attenuated the ER stress-induced cleavage of caspase-9,
      which is caused by intrinsic pathway activation.
    explanation: This supports ER-stress-linked apoptotic signaling in FECD-derived corneal endothelial cells.
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The molecular mechanisms associated with Fuchs endothelial corneal
      dystrophy, such as endoplasmic reticulum stress and unfolded protein
      response pathway, oxidative stress, mitochondrial dysregulation pathway,
      apoptosis pathway, mitophagy, epithelial-mesenchymal transition pathway,
      RNA toxicity and repeat-associated non-ATG translation, and other
      pathogenesis, were then explored.
    explanation: The review identifies apoptosis among reported FECD molecular mechanisms.
- name: Descemet Membrane Guttae
  description: >-
    FECD produces extracellular excrescences called guttae on a thickened
    Descemet membrane, creating the characteristic posterior corneal dystrophy
    morphology.
  locations:
  - preferred_term: cornea
    term:
      id: UBERON:0000964
      label: cornea
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: ABNORMAL
  downstream:
  - target: Descemet Membrane Abnormality
    description: Guttae and thickening are the morphologic basis of abnormal Descemet membrane morphology.
    causal_link_type: DIRECT
  - target: Corneal Opacity
    description: Guttae and edema reduce posterior corneal optical quality.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "excrescences on a thickened Descemet membrane (corneal guttae)"
    explanation: Orphanet defines FECD by corneal guttae on a thickened Descemet membrane.
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its main clinical signs are an accelerated decrease in the number of
      endothelial cells, thickening of Descemet's membrane and formation of
      guttae in the extracellular matrix.
    explanation: This review identifies endothelial-cell loss, Descemet membrane thickening, and guttae as principal FECD signs.
- name: Endothelial Cell Depletion
  description: >-
    Progressive reduction in corneal endothelial cell number lowers endothelial
    reserve and contributes to corneal edema and loss of transparency.
  cell_types:
  - preferred_term: corneal endothelial cell
    term:
      id: CL:0000132
      label: corneal endothelial cell
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  downstream:
  - target: Reduced Corneal Endothelial Cell Count
    description: Clinical measurement shows reduced numbers of corneal endothelial cells.
    causal_link_type: DIRECT
  - target: Corneal Edema
    description: Reduced endothelial cell reserve impairs corneal dehydration.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its main clinical signs are an accelerated decrease in the number of
      endothelial cells, thickening of Descemet's membrane and formation of
      guttae in the extracellular matrix.
    explanation: This supports progressive endothelial-cell depletion as a core FECD clinical feature.
phenotypes:
- category: Ophthalmological
  name: Corneal Edema
  frequency: VERY_FREQUENT
  description: >-
    Generalized corneal edema is a very frequent FECD manifestation and is the
    direct clinical consequence of impaired endothelial deturgescence.
  phenotype_term:
    preferred_term: corneal edema
    term:
      id: HP:0000969
      label: Edema
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000969 | Edema | Very frequent (99-80%)"
    explanation: Orphanet lists edema as very frequent in FECD; the disease definition specifies corneal edema.
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "generalized corneal edema"
    explanation: Orphanet's definition localizes the edema to the cornea.
- category: Ophthalmological
  name: Reduced Visual Acuity
  frequency: VERY_FREQUENT
  description: >-
    Visual acuity gradually declines as corneal edema and opacity increase.
  phenotype_term:
    preferred_term: reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007663 | Reduced visual acuity | Very frequent (99-80%)"
    explanation: Orphanet lists reduced visual acuity as very frequent in FECD.
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "gradually decreased visual acuity"
    explanation: Orphanet's definition explicitly includes gradual visual-acuity decline.
- category: Ophthalmological
  name: Corneal Opacity
  frequency: VERY_FREQUENT
  description: >-
    Loss of corneal clarity from edema, guttae, and endothelial failure produces
    corneal opacity.
  phenotype_term:
    preferred_term: corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007957 | Corneal opacity | Very frequent (99-80%)"
    explanation: Orphanet lists corneal opacity as very frequent in FECD.
- category: Ophthalmological
  name: Abnormal Corneal Endothelium Morphology
  frequency: VERY_FREQUENT
  description: >-
    FECD is centered on structural and functional abnormalities of the corneal
    endothelium.
  phenotype_term:
    preferred_term: abnormal corneal endothelium morphology
    term:
      id: HP:0011488
      label: Abnormal corneal endothelium morphology
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011488 | Abnormal corneal endothelium morphology | Very frequent (99-80%)"
    explanation: Orphanet lists abnormal corneal endothelium morphology as very frequent in FECD.
- category: Ophthalmological
  name: Descemet Membrane Abnormality
  frequency: VERY_FREQUENT
  description: >-
    Thickening of Descemet membrane with corneal guttae is a defining FECD
    morphologic abnormality.
  phenotype_term:
    preferred_term: abnormal Descemet membrane morphology
    term:
      id: HP:0011490
      label: Abnormal Descemet membrane morphology
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011490 | Abnormal Descemet membrane morphology | Very frequent (99-80%)"
    explanation: Orphanet lists abnormal Descemet membrane morphology as very frequent in FECD.
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "thickened Descemet membrane (corneal guttae)"
    explanation: Orphanet's definition specifies the Descemet membrane abnormality.
- category: Ophthalmological
  name: Reduced Corneal Endothelial Cell Count
  frequency: VERY_FREQUENT
  description: >-
    Loss of corneal endothelial cells is a very frequent FECD finding.
  phenotype_term:
    preferred_term: reduced number of corneal endothelial cells
    term:
      id: HP:0011491
      label: Reduced number of corneal endothelial cells
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011491 | Reduced number of corneal endothelial cells | Very frequent (99-80%)"
    explanation: Orphanet lists reduced numbers of corneal endothelial cells as very frequent in FECD.
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its main clinical signs are an accelerated decrease in the number of
      endothelial cells, thickening of Descemet's membrane and formation of
      guttae in the extracellular matrix.
    explanation: This review directly supports accelerated endothelial-cell loss as a main clinical sign.
- category: Ophthalmological
  name: Visual Loss
  frequency: FREQUENT
  description: >-
    Advanced FECD can cause clinically significant vision loss.
  phenotype_term:
    preferred_term: visual loss
    term:
      id: HP:0000572
      label: Visual loss
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000572 | Visual loss | Frequent (79-30%)"
    explanation: Orphanet lists visual loss as frequent in FECD.
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Advanced FECD, treatable only by corneal transplantation, is characterized
      by extensive guttae, endothelial cell loss, and vision loss due to stromal
      edema.
    explanation: This human FECD study links advanced disease to vision loss due to stromal edema.
- category: Ophthalmological
  name: Nyctalopia
  frequency: FREQUENT
  description: >-
    Orphanet lists nyctalopia as a frequent FECD phenotype. Primary FECD
    literature more commonly emphasizes glare, reduced contrast, and reduced
    visual acuity, so this assertion is retained specifically as an Orphanet
    phenotype.
  phenotype_term:
    preferred_term: nyctalopia
    term:
      id: HP:0000662
      label: Nyctalopia
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000662 | Nyctalopia | Frequent (79-30%)"
    explanation: Orphanet lists nyctalopia as frequent in FECD.
- category: Ophthalmological
  name: Eye Movement-Induced Pain
  frequency: FREQUENT
  description: >-
    Orphanet lists eye movement-induced pain as frequent. Painful epithelial
    bullae can occur when endothelial failure produces corneal edema.
  phenotype_term:
    preferred_term: eye movement-induced pain
    term:
      id: HP:0030857
      label: Eye movement-induced pain
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030857 | Eye movement-induced pain | Frequent (79-30%)"
    explanation: Orphanet lists eye movement-induced pain as frequent in FECD.
  - reference: PMID:34130750
    reference_title: "Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cornea's ability to maintain stromal dehydration is impaired, causing
      painful epithelial bullae and loss of vision
    explanation: The review supports corneal pain from epithelial bullae, though not specifically pain induced by eye movement.
genetic:
- name: TCF4 CTG repeat expansion and FECD susceptibility
  association: Disease-causing germline mutation(s) in
  gene_term:
    preferred_term: TCF4
    term:
      id: hgnc:11634
      label: TCF4
  features: >-
    TCF4 is listed by Orphanet as a disease-associated FECD gene, and the TCF4
    intronic CTG repeat expansion is the strongest common genetic association
    in late-onset FECD.
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TCF4 | transcription factor 4 | hgnc:11634 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists TCF4 as a disease-associated gene for FECD.
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the strongest association is with an intronic (CTG·CAG)n trinucleotide
      repeat expansion in the TCF4 gene
    explanation: This identifies the key TCF4 repeat-expansion association in FECD.
- name: COL8A2 disease-associated variants
  association: Disease-causing germline mutation(s) in
  gene_term:
    preferred_term: COL8A2
    term:
      id: hgnc:2216
      label: COL8A2
  features: >-
    Orphanet lists COL8A2 among disease-associated FECD genes.
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL8A2 | collagen type VIII alpha 2 chain | hgnc:2216 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists COL8A2 as a disease-associated gene for FECD.
- name: SLC4A11 disease-associated variants
  association: Disease-causing germline mutation(s) in
  gene_term:
    preferred_term: SLC4A11
    term:
      id: hgnc:16438
      label: SLC4A11
  features: >-
    Orphanet lists SLC4A11 among disease-associated FECD genes.
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC4A11 | solute carrier family 4 member 11 | hgnc:16438 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists SLC4A11 as a disease-associated gene for FECD.
- name: ZEB1 loss-of-function disease-associated variants
  association: Disease-causing germline mutation(s) in
  gene_term:
    preferred_term: ZEB1
    term:
      id: hgnc:11642
      label: ZEB1
  features: >-
    Orphanet lists ZEB1 loss-of-function variants among disease-associated FECD
    genes.
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ZEB1 | zinc finger E-box binding homeobox 1 | hgnc:11642 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet lists ZEB1 loss of function as disease-associated in FECD.
- name: AGBL1 disease-associated variants
  association: Disease-causing germline mutation(s) in
  gene_term:
    preferred_term: AGBL1
    term:
      id: hgnc:26504
      label: AGBL1
  features: >-
    Orphanet lists AGBL1 among disease-associated FECD genes.
  evidence:
  - reference: ORPHA:98974
    reference_title: "Fuchs endothelial corneal dystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "AGBL1 | AGBL carboxypeptidase 1 | hgnc:26504 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists AGBL1 as a disease-associated gene for FECD.
diagnosis:
- name: Slit-lamp and ophthalmic examination
  diagnosis_term:
    preferred_term: eye examination
    term:
      id: MAXO:0001155
      label: eye examination
  description: >-
    Routine ophthalmic examination, including slit-lamp biomicroscopy, can
    identify guttae and clinical stages of FECD.
  results: Corneal guttae, endothelial abnormalities, corneal edema, and reduced visual acuity support clinical diagnosis.
  evidence:
  - reference: PMID:32735996
    reference_title: "TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although the clinical identification of mild guttae can be achieved with
      routine slit lamp bio-microscopy
    explanation: This supports slit-lamp examination for clinical identification of guttae in FECD.
- name: Endothelial cell and corneal edema assessment
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  description: >-
    Endothelial cell density, guttae burden, corneal thickness, and imaging of
    edema help stage FECD and monitor progression.
  results: Reduced endothelial-cell density, increased guttae, and corneal edema support FECD severity assessment.
  evidence:
  - reference: PMID:32735996
    reference_title: "TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      outcome metrics are likely to entail both anatomical variables that
      reflect the density of endothelial cells and guttae, and functional
      variables that relate to Na+/K+ ATPase pump function in corneal
      endothelial cells.
    explanation: The review supports endothelial density, guttae burden, and corneal thickness as FECD assessment metrics.
  - reference: PMID:32735996
    reference_title: "TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Scheimpflug imaging of the cornea may be useful to identify and classify
      stages of edema due to endothelial dysfunction
    explanation: The review supports corneal imaging for staging edema due to endothelial dysfunction.
  - reference: PMID:31414054
    reference_title: "Towards Clinical Trials in Fuchs Endothelial Corneal Dystrophy: Classification and Outcome Measures-The Bowman Club Lecture 2019."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FECD, and the outcomes of interventions to treat the disease, can be
      measured in terms of corneal morphology, corneal function and clinical
      impact.
    explanation: This supports combined morphologic, functional, and clinical assessment for FECD staging and intervention outcomes.
- name: Molecular genetic testing
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  description: >-
    Molecular genetic testing can evaluate familial FECD genes and TCF4 CTG
    repeat expansion when genetic clarification is clinically indicated.
  results: Pathogenic variants or TCF4 CTG repeat expansion support inherited or genetically susceptible FECD.
  evidence:
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the strongest association is with an intronic (CTG·CAG)n trinucleotide
      repeat expansion in the TCF4 gene
    explanation: This supports TCF4 repeat testing as a genetically informative FECD assay.
treatments:
- name: Endothelial keratoplasty or corneal transplantation
  description: >-
    Endothelial keratoplasty, including DMEK or DSAEK, and corneal
    transplantation replace or restore endothelial function in visually
    significant advanced FECD.
  treatment_term:
    preferred_term: corneal transplantation
    term:
      id: MAXO:0010034
      label: corneal transplantation
  target_mechanisms:
  - target: Corneal Endothelial Barrier Dysfunction
    treatment_effect: RESTORES
    description: Endothelial transplantation restores the endothelial deturgescence function lost in advanced FECD.
  evidence:
  - reference: PMID:25593321
    reference_title: "RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Advanced FECD, treatable only by corneal transplantation, is characterized
      by extensive guttae, endothelial cell loss, and vision loss due to stromal
      edema.
    explanation: This directly supports corneal transplantation as treatment for advanced FECD.
  - reference: PMID:32735996
    reference_title: "TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The management of end-stage FECD has been revolutionized in developed
      countries by the introduction of endothelial keratoplasty that can rapidly
      and effectively restore vision.
    explanation: This review supports endothelial keratoplasty for end-stage FECD.
  - reference: PMID:32965936
    reference_title: "Corneal Endothelial Transplantation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared to DSAEK, DMEK has better visual outcomes, faster recovery time,
      and lower immune rejection rate.
    explanation: This supports DMEK as a modern endothelial keratoplasty option relevant to FECD transplantation care.
- name: Topical ripasudil after DWEK or phacoemulsification
  description: >-
    Topical ROCK inhibition with ripasudil has randomized clinical-trial
    evidence for accelerating corneal clearing after DWEK and reducing
    endothelial cell loss after phacoemulsification in FECD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ripasudil
      term:
        id: CHEBI:136046
        label: ripasudil
  target_mechanisms:
  - target: Corneal Endothelial Barrier Dysfunction
    treatment_effect: MODULATES
    description: ROCK inhibition improves endothelial recovery and corneal deturgescence in selected FECD surgical contexts.
  evidence:
  - reference: PMID:42018070
    reference_title: "Topical ROCK inhibition accelerates recovery after Descemetorhexis Without Endothelial Keratoplasty (DWEK) in Fuchs endothelial corneal dystrophy: a prospective comparative clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Adjunctive topical ripasudil after DWEK accelerates endothelial recovery,
      corneal deturgescence, and visual rehabilitation compared with DWEK alone,
      without compromising safety.
    explanation: This prospective randomized comparative clinical study supports adjunctive ripasudil after DWEK in mild-to-moderate FECD.
  - reference: PMID:39946654
    reference_title: "Efficacy of the Rho-Kinase Inhibitor for Corneal Endothelial Protection in Fuchs Endothelial Corneal Dystrophy After Phacoemulsification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The topical ROCK inhibitor, or ripasudil, demonstrated beneficial effects
      on preventing endothelial cell loss and improving endothelial function in
      patients with FECD undergoing phacoemulsification.
    explanation: This randomized trial supports ripasudil for endothelial protection after phacoemulsification in FECD.
clinical_trials:
- name: NCT04057053
  status: COMPLETED
  description: >-
    Trial of netarsudil after Descemetorhexis Without Endothelial Keratoplasty
    to assess whether ROCK inhibition speeds corneal clearance.
  evidence:
  - reference: clinicaltrials:NCT04057053
    reference_title: Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK."
    explanation: The ClinicalTrials.gov summary directly identifies the netarsudil-after-DWEK trial objective in FECD-related corneal clearance.
- name: NCT02653391
  status: COMPLETED
  description: >-
    Phase 1/2 trial evaluating topical elamipretide ophthalmic solution in
    people with Fuchs corneal endothelial dystrophy and mild-to-moderate corneal
    edema.
  evidence:
  - reference: clinicaltrials:NCT02653391
    reference_title: "Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema."
    explanation: The ClinicalTrials.gov summary supports a completed elamipretide trial in FCED with mild-to-moderate corneal edema.
references:
- reference: ORPHA:98974
  title: Fuchs endothelial corneal dystrophy
- reference: PMID:25593321
  title: RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy.
- reference: PMID:26937169
  title: "Fuchs endothelial corneal dystrophy: current perspectives."
- reference: PMID:28118661
  title: Trinucleotide Repeat Expansion in the Transcription Factor 4 (TCF4) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy.
- reference: PMID:28727885
  title: Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs' Endothelial Corneal Dystrophy.
- reference: PMID:31414054
  title: "Towards Clinical Trials in Fuchs Endothelial Corneal Dystrophy: Classification and Outcome Measures-The Bowman Club Lecture 2019."
- reference: PMID:32735996
  title: "TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease."
- reference: PMID:32965936
  title: Corneal Endothelial Transplantation.
- reference: PMID:33724294
  title: "Mitophagy: An Emerging Target in Ocular Pathology."
- reference: PMID:34130750
  title: Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy.
- reference: PMID:39946654
  title: Efficacy of the Rho-Kinase Inhibitor for Corneal Endothelial Protection in Fuchs Endothelial Corneal Dystrophy After Phacoemulsification.
- reference: PMID:42018070
  title: "Topical ROCK inhibition accelerates recovery after Descemetorhexis Without Endothelial Keratoplasty (DWEK) in Fuchs endothelial corneal dystrophy: a prospective comparative clinical trial."
- reference: clinicaltrials:NCT04057053
  title: Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
- reference: clinicaltrials:NCT02653391
  title: "Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema."
datasets: []
📚

References & Deep Research

References

14
ORPHA:98974
Fuchs endothelial corneal dystrophy
No top-level findings curated for this source.
PMID:25593321
RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy.
No top-level findings curated for this source.
PMID:26937169
Fuchs endothelial corneal dystrophy: current perspectives.
No top-level findings curated for this source.
PMID:28118661
Trinucleotide Repeat Expansion in the Transcription Factor 4 (TCF4) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy.
No top-level findings curated for this source.
PMID:28727885
Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs' Endothelial Corneal Dystrophy.
No top-level findings curated for this source.
PMID:31414054
Towards Clinical Trials in Fuchs Endothelial Corneal Dystrophy: Classification and Outcome Measures-The Bowman Club Lecture 2019.
No top-level findings curated for this source.
PMID:32735996
TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease.
No top-level findings curated for this source.
PMID:32965936
Corneal Endothelial Transplantation.
No top-level findings curated for this source.
PMID:33724294
Mitophagy: An Emerging Target in Ocular Pathology.
No top-level findings curated for this source.
PMID:34130750
Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy.
No top-level findings curated for this source.
PMID:39946654
Efficacy of the Rho-Kinase Inhibitor for Corneal Endothelial Protection in Fuchs Endothelial Corneal Dystrophy After Phacoemulsification.
No top-level findings curated for this source.
PMID:42018070
Topical ROCK inhibition accelerates recovery after Descemetorhexis Without Endothelial Keratoplasty (DWEK) in Fuchs endothelial corneal dystrophy: a prospective comparative clinical trial.
No top-level findings curated for this source.
clinicaltrials:NCT04057053
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
No top-level findings curated for this source.
clinicaltrials:NCT02653391
Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema.
No top-level findings curated for this source.

Deep Research

1
Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Fuchs Endothelial Corneal Dystrophy. Core disease mechanisms, molecular an...
Asta Scientific Corpus Retrieval 17 citations 2026-05-11T11:16:01.858331

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Fuchs Endothelial Corneal Dystrophy. Core disease mechanisms, molecular an...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 17
  • Snippets retrieved: 20

Relevant Papers

[1] Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy

  • Authors: Xue Liu, Tao Zheng, Chuchu Zhao, Yi Zhang, Hanruo Liu et al.
  • Year: 2021
  • Venue: Eye and Vision
  • URL: https://www.semanticscholar.org/paper/12e7cdcdc924d1fde2012ef77fd55d89c3d6957d
  • DOI: 10.1186/s40662-021-00246-2
  • PMID: 34130750
  • PMCID: 8204469
  • Citations: 25
  • Influential citations: 2
  • Summary: The mutations of COL8A2, TCF4 , TCF8 , SLC4A11 and AGBL1 genes in Fuchs endothelial corneal dystrophy are summarized and several potential treatments related to the pathogenesis of Fuchs vascular disease are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.837) > Background Fuchs endothelial corneal dystrophy is a hereditary disease and the most frequent cause of corneal transplantation in the worldwide. Its main clinical signs are an accelerated decrease in the number of endothelial cells, thickening of Descemet’s membrane and formation of guttae in the extracellular matrix. The cornea’s ability to maintain stromal dehydration is impaired, causing painful epithelial bullae and loss of vision at the point when the amount of corneal endothelial cells cannot be compensated. At present, apart from corneal transplantation, there is no other effective treatment that prevents blindness. Main text In this review, we first summarized the mutations of COL8A2 , TCF4 , TCF8 , SLC4A11 and AGBL1 genes in Fuchs endothelial corneal dystrophy. The molecular mechanisms associated with Fuchs endothelial corneal dystrophy, such as endoplasmic reticulum stress and unfolded protein response pathway, oxidative stress, mitochondrial dysregulation pathway, apoptosis pathway, mitophagy, epithelial-mesenchymal transition pathway, RNA toxicity and repeat-associated non-ATG translation, and other pathogenesis, were then explored. Finally, we discussed several potential treatments related to the pathogenesis of Fuchs endothelial corneal dystrophy, which may be the focus of future research. Conclusions The pathogenesis of Fuchs endothelial corneal dystrophy is very complicated. Currently, corneal transplantation is an important method in the treatment of Fuchs endothelial corneal dystrophy. It is necessary to continuously explore the pathogenesis of Fuchs endothelial corneal dystrophy and establish the scientific foundations for the development of next-generation corneal therapeutics.

[2] Fuchs endothelial corneal dystrophy: current perspectives

  • Authors: Gustavo Vedana, G. Villarreal, A. Jun
  • Year: 2016
  • Venue: Clinical Ophthalmology (Auckland, N.Z.)
  • URL: https://www.semanticscholar.org/paper/5e711677fe86955a62fc79446631a033649025dd
  • DOI: 10.2147/OPTH.S83467
  • PMID: 26937169
  • PMCID: 4762439
  • Citations: 120
  • Influential citations: 6
  • Summary: Advances that have been made in understanding FECD’s clinical features, pathophysiology, and genetics are highlighted and recent advances in endothelial keratoplasty are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.693) > Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane. Later stages involve all layers of the cornea. Impairment of endothelial barrier and pump function and cell death from oxidative and unfolded protein stress contribute to disease progression. The genetic basis of FECD includes numerous genes and chromosomal loci, although alterations in the transcription factor 4 gene are associated with the majority of cases. Definitive treatment of FECD is corneal transplantation. In this paper, we highlight advances that have been made in understanding FECD’s clinical features, pathophysiology, and genetics. We also discuss recent advances in endothelial keratoplasty and potential future treatments.
  • Snippet 2 (score: 0.621) > Fuchs endothelial corneal dystrophy (FECD) was first described by Professor Ernst Fuchs as "Dystrophia epithelialis" more than 100 years ago, when he noticed a pattern of slowly progressive corneal clouding with greater involvement of the inferior cornea, reduced corneal sensation, and diurnal variation in symptoms affecting primarily the epithelium in elderly patients. 1 Six years later with the development of the slit lamp biomicroscope, Koeppe observed the classic finding of guttae in the corneal endothelium of patients with the corneal edema described by Fuchs. 2 Subsequent authors found different clinical signs associated with the dystrophy including progression of endothelial changes to corneal edema, 2 reduced corneal endothelial cell (CEC) density with abnormal size and shape, formation of a markedly thickened Descemet's membrane (DM) containing guttae excrescences, spindle-shaped bundles of wide-spaced collagen, and the hereditary nature of the disease. 2,3 During the past 100 years, studies of pathophysiology have increased our understanding of this disease, and improved treatments have been developed. The aim of this paper was to review relevant information about FECD and provide current perspectives on this disorder. endothelium Human corneal endothelium is in a postmitotic state and postnatal cell loss is permanent. In FECD, dying cells leave spaces that are filled through the expansion of adjacent cells resulting in loss of cellular hexagonal morphology (pleomorphism) and variation in cell size (polymegathism). Extracellular matrix excrescences (guttae) appear as round dark areas within the cellular monolayer on specular microscopy. 8,11,20 In early-onset FECD, endothelial cells were highly active in producing more COL8 protein than normal and displayed an abundant, unusual RER. In late-onset FECD, melanin was found intracellularly and extracellularly, together with expanded RER, dilated mitochondria, and epithelial markers. These findings suggest that endothelial cells undergo metaplasia becoming more similar to fibroblasts and epithelial cells in FECD

[3] Animal Models in Eye Research: Focus on Corneal Pathologies

  • Authors: Alexis Loiseau, Gabrielle Raîche-Marcoux, Cloé Maranda, Nicolas Bertrand, Élodie Boisselier
  • Year: 2023
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/57e3924f29f7e81714289adbb30fa31f98be3bc8
  • DOI: 10.3390/ijms242316661
  • PMID: 38068983
  • PMCID: 10706114
  • Citations: 45
  • Influential citations: 1
  • Summary: This review discusses current animal models associated with human corneal pathologies, their utility in understanding ocular disease mechanisms, and their role as translational models for patients.
  • Evidence snippets:
  • Snippet 1 (score: 0.687) > Vision loss is also the primary symptom in patients with endothelial corneal dystrophies due to fluid retention (swelling of the cornea), leading to corneal edema which results in progressive loss of corneal transparency [252,[254][255][256][257][258]. This type of corneal dystrophy accounts for approximately 60% of all types of corneal dystrophies [252]. The discovery of the genetic basis of corneal dystrophies is not complete, and the molecular mechanisms of the different mutations in the pathogenesis of each corneal dystrophy remain unclear. The development of gene therapy in the initial stages of corneal dystrophies is an important scientific challenge for the future. In contrast to retinal dystrophies, corneal dystrophies are more amenable to such therapy because of the anatomical accessibility of the cornea [254]. > Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy, with a prevalence ranging from 3 to 11% depending on the age, ethnicity, and sex of the population [255][256][257][258][259]. This genetically heterogeneous disease is the most frequent cause of corneal transplantation worldwide. Two forms of FECD exist-the rare early-onset form and the more common late-onset form [252,255,257]. Although the primary cause of this disease is unknown [254,260], this bilateral disease of the corneal endothelium is characterized by accelerated loss of corneal endothelial cells and the formation of extracellular matrix excrescences in Descemet's membrane, called guttae [256][257][258][259]. Endothelial cell oxidative stress, apoptosis, loss of pump function, and deposition of abnormal extracellular matrix occur in the initial stages of the disease. These responses are manifested by endothelial cell loss, enlargement, and change in morphology associated with Descemet's membrane thickening and guttae formation, leading to corneal edema until vision is lost.

[4] Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy

  • Authors: Sohya Fujimoto, Mako Endo, Shigehito Tonomura, Fuuga Tsuji, Hirotaka Haraguchi et al.
  • Year: 2025
  • Venue: Cells
  • URL: https://www.semanticscholar.org/paper/0b6bd849ac02058de9ae66c789e2582173e4689e
  • DOI: 10.3390/cells14070498
  • PMID: 40214452
  • PMCID: 11988121
  • Citations: 3
  • Summary: It is suggested that emricasan exerts dual protective effects by inhibiting caspase-7-mediated ECM accumulation and broadly suppressing apoptosis, highlighting its potential as a pharmacological therapy for FECD.
  • Evidence snippets:
  • Snippet 1 (score: 0.680) > Fuchs endothelial corneal dystrophy (FECD) is a progressive eye disease characterized by the formation of guttae, excrescences of Descemet membrane, and corneal endothelial cell degeneration [1][2][3]. The disease typically begins with the formation of central guttae, which, as they become more confluent, cause light scatter and consequent visual impairment [4,5]. As the disease progresses, corneal endothelial dysfunction advances until the remaining endothelial cells can no longer maintain corneal deturgescence, resulting in corneal edema and severe vision loss [1][2][3]. While corneal transplantation remains the standard treatment for FECD, several challenges persist, including a global donor cornea shortage (particularly outside the United States), immune rejection, and long-term graft failure due to continued endothelial cell loss [6][7][8][9][10]. These limitations underscore the urgent need for alternative therapeutic approaches, particularly pharmacological interventions. > Various molecular pathways contribute to FECD pathogenesis, with apoptotic cell death representing a central mechanism supported by substantial evidence [3]. Corneal endothelial cells (CECs) in FECD patients demonstrate enhanced vulnerability to apoptosis triggered by oxidative stress compared with endothelial cells from healthy controls [11,12]. This susceptibility stems from multiple factors, including accumulated oxidative damage to DNA (particularly affecting mitochondrial DNA) and compromised antioxidant defense systems [11]. Cell death in FECD is further promoted by chronic activation of the unfolded protein response pathway [13][14][15]. The disease progression is accelerated by dysfunctional mitochondria and defective mitophagy mechanisms [16]. Moreover, the characteristic guttae formations trigger apoptotic cascades in adjacent CECs, establishing a self-perpetuating cycle of cellular degeneration [17]. These insights into FECD pathogenesis, particularly the pivotal role of apoptosis in disease progression, suggest that targeting apoptotic pathways could offer a promising therapeutic approach for FECD.

[5] The Sociodemographic and Risk Factors for Fuchs’ Endothelial Dystrophy: A Nationwide, Matched Case–Control Study in Taiwan

  • Authors: Yuh-Shin Chang, Chung‐Han Ho, Jhi-Joung Wang, S. Tseng, Ren-Long Jan
  • Year: 2022
  • Venue: Journal of Personalized Medicine
  • URL: https://www.semanticscholar.org/paper/3aa8aeb16188d0d89b3d5083336df4ba1c705bb7
  • DOI: 10.3390/jpm12020305
  • PMID: 35207793
  • PMCID: 8877330
  • Citations: 2
  • Summary: It is found that more than half of the FED patients in Taiwan were aged ≥45 years old, there was an equal female-to-male ratio (1.06:1), and patients with a lower income and living in northern Taiwan had higher odds of developing FED.
  • Evidence snippets:
  • Snippet 1 (score: 0.670) > Fuchs' corneal endothelial dystrophy (FED), the most common form of corneal dystrophy, affects the endothelium, which is the innermost layer of the cornea. FED is characterized by endothelial cell density reduction with endothelium cell morphology alterations including variation in cell shape, known as cellular pleomorphism, and variation in the cell size, known as polymegathism [1]. FED usually presents in the fifth decade of life and progresses over the next two to three decades with continued endothelium cell loss and dysfunction. Some FED patients may be asymptomatic in the early stages of the disease, but patients may have glare or reduced visual acuity, severe pain due to the corneal edema progression to stromal thickness, increased bulla formation, or even long-standing corneal vascularization [2]. > FED is a multifactorial disorder caused by a complex combination of genetic, biochemistry, biology, and environmental factors. The pathophysiology of FED remains unknown, although several proposed mechanisms have been reported [1,[3][4][5]. Channelopathy, related to mutations in the genes of the ion channels in the corneal endothelium appears to be an important pathogenetic factor in the development of FED [3,4]. Elevation of oxidative stress and reactive oxygen species accumulation could lead to apoptosis of endothelial cells and is also regarded as one major cause of the development of FED [1,4]. The epithelialmesenchymal transition, in which fibroblastic or epithelial cell phenotypes transform from endothelial cells, could result in the secretion of extracellular matrix proteins leading to abnormal deposition, is thought to be involved in the pathogenesis of FED [1,4,5]. > The estimated incidence and prevalence of FED varies greatly worldwide, with a higher prevalence in Europe and the USA and lower rates in Asia, possibly because of different genetic or environmental factors and a difference in clinical definitions of FED [6,7]. Being older than 40 years of age is a major risk factor for FED development [4,5,8].

[6] Towards Clinical Trials in Fuchs Endothelial Corneal Dystrophy: Classification and Outcome Measures—The Bowman Club Lecture 2019

  • Authors: Sanjay V. Patel
  • Year: 2019
  • Venue: BMJ Open Ophthalmology
  • URL: https://www.semanticscholar.org/paper/fdd57258229919cdb109d3ca9a65407ef3533fb4
  • DOI: 10.1136/bmjophth-2019-000321
  • PMID: 31414054
  • PMCID: 6668606
  • Citations: 25
  • Summary: Standardising the approach for defining FECD and careful thought about the outcomes of intervention that are reported will help make the results of future trials for FECD applicable in clinical practice.
  • Evidence snippets:
  • Snippet 1 (score: 0.633) > The surgical treatment of Fuchs endothelial corneal dystrophy (FECD) has advanced dramatically over the last two decades. Penetrating keratoplasty has been superseded by various iterations of endothelial keratoplasty, and currently, surgical removal of host Descemet membrane without keratoplasty is being investigated. These surgical advances have been accompanied by significant improvement of our understanding of the underlying disease mechanisms, not least the discovery that FECD in western populations is predominantly an intronic trinucleotide repeat expansion disorder in the transcription factor 4 gene that results in RNA toxicity and mis-splicing. Understanding the disease mechanisms augurs well for developing targeted molecular medical therapies, which will require careful clinical investigation through trials to prove their efficacy and safety. As the field advances towards clinical trials, investigators should carefully define the disease state being treated and consider the options for outcome measures relevant to the type of intervention. FECD, and the outcomes of interventions to treat the disease, can be measured in terms of corneal morphology, corneal function and clinical impact. Standardising the approach for defining FECD and careful thought about the outcomes of intervention that are reported will help make the results of future trials for FECD applicable in clinical practice.
  • Snippet 2 (score: 0.633) > The surgical treatment of Fuchs endothelial corneal dystrophy (FECD) has advanced dramatically over the last two decades. Penetrating keratoplasty has been superseded by various iterations of endothelial keratoplasty, and currently, surgical removal of host Descemet membrane without keratoplasty is being investigated. These surgical advances have been accompanied by significant improvement of our understanding of the underlying disease mechanisms, not least the discovery that FECD in western populations is predominantly an intronic trinucleotide repeat expansion disorder in the transcription factor 4 gene that results in RNA toxicity and mis-splicing. Understanding the disease mechanisms augurs well for developing targeted molecular medical therapies, which will require careful clinical investigation through trials to prove their efficacy and safety. As the field advances towards clinical trials, investigators should carefully define the disease state being treated and consider the options for outcome measures relevant to the type of intervention. FECD, and the outcomes of interventions to treat the disease, can be measured in terms of corneal morphology, corneal function and clinical impact. Standardising the approach for defining FECD and careful thought about the outcomes of intervention that are reported will help make the results of future trials for FECD applicable in clinical practice.

[7] Characterisation of the role played by ELMO1, GPR141 and the intergenic polymorphism rs918980 in Fuchs' dystrophy in the Indian population

  • Authors: Susmita Sharma, S. K. Basak, Sujata Das, D. P. Alone
  • Year: 2025
  • Venue: FEBS Open Bio
  • URL: https://www.semanticscholar.org/paper/214fe9d2f1a4e46ec64aca4291e02f3b0d6d7f43
  • DOI: 10.1002/2211-5463.70006
  • PMID: 39967558
  • PMCID: 12051025
  • Citations: 1
  • Summary: The results suggest that ELMO1 and GPR141 might play a significant role in FECD progression, however, further studies are required to better characterize the possible role of rs918980 and its nearby region in the regulation of ELMO1 and GPR141.
  • Evidence snippets:
  • Snippet 1 (score: 0.629) > The innermost part of the human cornea, the corneal endothelium (CE), plays a vital role in vision and is present on the Descemet membrane [1]. CE consists of corneal endothelial cells (CECs), which are enriched with Na + -K + ATPase, aquaporin and other channel proteins that regulate the water and ions exchange between the corneal stroma and aqueous humor, keeping the avascular cornea in a hydrated condition and maintains corneal clarity [2,3]. Dysregulation of these proteins leads to water retention in the corneal stroma, resulting in thickened Descemet's membrane, increased extracellular matrix (ECM) protein deposition, CECs loss, guttae formation, painful epithelial bullae leading to Fuchs' endothelial corneal dystrophy (FECD) [4][5][6][7]. Cellular and molecular mechanisms such as endothelial pump dysfunction, endothelial-mesenchymal transition (EndoMT), RNA toxicity, oxidative stress, apoptosis, mitophagy and unfolded protein response pathway dysregulation contribute to the disease [8]. FECD, the most common type of primary corneal dystrophy, was Abbreviations CE, corneal endothelium; CEC, corneal endothelial cell; DSEK, Descemet stripping endothelial keratoplasty; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; EndoMT, endothelial-mesenchymal transition; FECD, Fuchs endothelial corneal dystrophy; IL, interleukin; LVPEI, LV Prasad Eye Institute; NFκB, nuclear factor kappa B; qRT-PCR, quantitative real-time PCR; SNP, single nucleotide polymorphism; TF, transcription factor; TGF, transforming growth factor; UVA, ultraviolet A. > first reported by Ernst Fuchs in 1910 and follows an autosomal dominant inheritance pattern in families.

[8] Update on the genetics of corneal endothelial dystrophies

  • Authors: C. Kannabiran, S. Chaurasia, Muralidhar Ramappa, V. Mootha
  • Year: 2022
  • Venue: Indian Journal of Ophthalmology
  • URL: https://www.semanticscholar.org/paper/3080a90259e7d8e711648196c9dbb44611bdc589
  • DOI: 10.4103/ijo.IJO_992_22
  • PMID: 35791103
  • PMCID: 9426112
  • Citations: 17
  • Summary: Knowledge of the genetics of corneal endothelial dystrophies has considerably advanced within the last decade and has contributed to better diagnosis of these dystrophic diseases as well as opened up the possibility of novel therapeutic approaches based on the molecular mechanisms involved.
  • Evidence snippets:
  • Snippet 1 (score: 0.626) > Corneal endothelial dystrophies are a heterogeneous group of diseases with different modes of inheritance and genetic basis for each dystrophy. The genes associated with these diseases encode transcription factors, structural components of the stroma and Descemet membrane, cell transport proteins, and others. Congenital hereditary endothelial dystrophy (CHED) is associated with mutations in two genes, OVOL2 and SLC4A11, for dominant and recessive forms of CHED, respectively. Mutations in three genes are known to cause posterior polymorphous corneal dystrophy (PPCD). They are OVOL2 (PPCD1), ZEB1 (PPCD3), and GRHL1 (PPCD4). The PPCD2 locus involving the collagen gene COL8A2 on chromosome 1 is disputed due to insufficient evidence. Mutations in the COL8A2 gene are associated with early-onset Fuchs' endothelial corneal dystrophy (FECD). Several genes have been associated with the more common, late-onset FECD. Alterations in each of these genes occur in a fraction of patients, and the most prevalent genetic alteration in FECD patients across the world is a triplet repeat expansion in the TCF4 gene. Knowledge of the genetics of corneal endothelial dystrophies has considerably advanced within the last decade and has contributed to better diagnosis of these dystrophies as well as opened up the possibility of novel therapeutic approaches based on the molecular mechanisms involved. The functions of genes identified to date provide insights into the pathogenic mechanisms involved in each disorder.
  • Snippet 2 (score: 0.622) > Many recent advances in the genetics of corneal endothelial dystrophies have brought to light pathways and mechanisms underlying the development of these diseases and pointed to correlations between genotype and phenotype. Despite a high degree of genetic heterogeneity, particularly for PPCD and FECD, the prevalence of mutations in the existing genes are rapidly being defined in patients from different regions. The application of genome sequencing may further facilitate the identification of new loci or novel types of pathogenic changes in existing genes in the near future and enhance our understanding of the underlying genetics of these diseases. A significant corollary of the new developments in the field lies in the possibility of developing suitable new therapies for these disorders based on their known genetic and molecular mechanisms. Proof of concept has already been obtained for using specific approaches to inhibit the triplet repeat expansionmediated disease pathways in FECD. Genetic screening may aid in establishing a genotype-phenotype correlation for patients. In a majority of cases, a meticulous slit-lamp examination and histological analysis wherever available help in determining the exact nature of the endothelial disease, although a diagnosis in patients with unusual manifestations can be supported by genetic testing. In familial forms of PPCD, knowing the mutation can aid in early screening and detection of affected but asymptomatic individuals. Developments in genetics have improved our knowledge of the corneal endothelial dystrophies and reduced the inaccuracies in their nomenclature. An accurate diagnosis of the specific type of endothelial dystrophy assists in planning the most appropriate management strategy and prognostication of the clinical condition. Furthermore, with the advent of alternatives such as pharmacotherapy and targeted molecular therapy in the management of endothelial dystrophies, a precise diagnosis of the clinical phenotype has become increasingly paramount.

[9] Oxidative Stress and Cellular Protein Accumulation Are Present in Keratoconus, Macular Corneal Dystrophy, and Fuchs Endothelial Corneal Dystrophy

  • Authors: Linda Vottonen, A. Koskela, S. Felszeghy, Adam Wylęgała, Katarzyna Kryszan et al.
  • Year: 2023
  • Venue: Journal of Clinical Medicine
  • URL: https://www.semanticscholar.org/paper/c903728f6001fc361af98b67b3b9288d27a17eb9
  • DOI: 10.3390/jcm12134332
  • PMID: 37445366
  • PMCID: 10342758
  • Citations: 13
  • Summary: Results suggest that oxidative stress has a role in KC, MCD, and FECD at the cellular level as a secondary outcome, and antioxidant- and autophagy-targeted therapies could be included as supporting care when treating KC or corneal dystrophies.
  • Evidence snippets:
  • Snippet 1 (score: 0.624) > The main function of the endothelium is to maintain a healthy stroma by regulating stromal hydration and nutrition as the cornea lacks its own blood supply [8]. The nutrients for the endothelium and stromal cells must be derived from the aqueous humor located at the more posterior side. > Due to its important role as a refractive interface, corneal diseases, such as corneal dystrophies and keratoconus, threaten normal vision and affect patients' quality of life. Corneal dystrophies can be classified as epithelial and subepithelial, epithelial-stromal, stromal, and endothelial dystrophies [9]. However, these dystrophies are not restricted to a certain layer and can also influence acellular layers [4]. Corneal dystrophies are often inherited and noninflammatory conditions without systemic manifestations. Gradual progression is also a common nominator of corneal dystrophies. Despite the clear link between inheritance and disease prevalence, little is known about the pathological and molecular mechanisms involved in disease onset and progression. > Oxidative stress has been linked to keratoconus (KC), macular corneal dystrophy (MCD), and Fuchs endothelial corneal dystrophy (FECD) [10,11]. Other known corneal conditions to which oxidative stress is associated are pterygium, trauma, and chemical injury [12]. KC is a corneal disease affecting the epithelium, Bowman's layer, and stroma. It usually begins in puberty and is progressive until 30-40 years of age [13]. KC is the most common primary ectasia, which results in irregular astigmatism, myopia, and reduced visual acuity [14]. MCD is a stromal dystrophy in which the deposition of abnormal proteoglycans leads to loss of corneal transparency and decreased vision [15]. The disease usually begins between 10 and 30 years of age and is recognized throughout the world. The prevalence seems to be higher in communities where consanguinity is common.

[10] Mitophagy: An Emerging Target in Ocular Pathology

  • Authors: Jessica M. Skeie, D. Nishimura, Cheryl L. Wang, Gregory A. Schmidt, B. T. Aldrich et al.
  • Year: 2021
  • Venue: Investigative Ophthalmology & Visual Science
  • URL: https://www.semanticscholar.org/paper/0fce0ac8cdf8590910e18cd3f74c86e96461e919
  • DOI: 10.1167/iovs.62.3.22
  • PMID: 33724294
  • PMCID: 7980050
  • Citations: 47
  • Summary: It is imperative that mitophagy be investigated as a targetable mechanism in developing therapies for ocular diseases characterized by oxidative stress and mitochondrial dysfunction, as this review indicates.
  • Evidence snippets:
  • Snippet 1 (score: 0.614) > anterior chamber, 79 have high rates of mitochondrial activity as they utilize active ion pumping mechanisms to counteract the passive leak of aqueous humor into the stroma, and do not proliferate in response to injury. With the emergence of single-layer endothelial cell transplant techniques (Descemet membrane endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty [DSAEK]), it has become imperative to understand these cells in more detail in order to maximize the success of surgical outcomes. Two common diseases that feature impaired CEC function, Fuchs endothelial corneal dystrophy (FECD) and diabetes mellitus, demonstrate the effects of altered mitophagy on disease progression, as discussed below. Fuchs Endothelial Corneal Dystrophy. FECD, the most prevalent indication for endothelial keratoplasty in the United States, 80 manifests as a result of genetic mutations (spontaneous and familial), as well as non-heritable risk factors including gender (female predominance) and smoking. The clinical hallmarks of FECD include cell death and extracellular matrix deposition, resulting in corneal edema and characteristic excrescences observable on the posterior cornea (guttae). 81 Cellular and ultracellular characteristics of FECD include channel protein dysfunction, mitochondrial dysfunction, ROS accumulation, ER stress, DNA alterations, unfolded protein response, and endothelial cell apoptosis/dropout. 81,82 Although FECD is a complex disease with several different primary mechanisms involved, secondary mitochondrial dysfunction and mitophagy play a central role in the decline of endothelial cell viability during the progression of this disease. > Halilovic et al. 83 showed that corneas from FECD patients have increased mtDNA damage, and expanded ex vivo FECD cells have decreased ATP production as a result of oxidative stress. These findings indicate that reduced mitochondrial respiratory capacity and reduced mitochondrial protein expression are central features of the FECD cellular disease phenotype. Importantly, ATP production deficits were rescued with the antioxidant N-acetylcysteine (NAC), indicating the importance of maintaining proper redox balance in CEC function. Furthermore, Ben

[11] Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review

  • Authors: Chulpan B Kharisova, K. Kitaeva, V. Solovyeva, A. A. Sufianov, G. Z. Sufianova et al.
  • Year: 2025
  • Venue: Biomedicines
  • URL: https://www.semanticscholar.org/paper/9b18df124d45c5161f6ab2880a2a419186682de7
  • DOI: 10.3390/biomedicines13020365
  • PMID: 40002778
  • PMCID: 11852528
  • Citations: 14
  • Influential citations: 2
  • Summary: A review examines the concept of gene therapy and its application in the field of ocular pathologies, emphasizing the most recent scientific advances and their potential impacts on visual function status.
  • Evidence snippets:
  • Snippet 1 (score: 0.613) > Corneal dystrophies are a heterogeneous group of inherited diseases of the cornea accompanied by corneal damage. This pathology is classified depending on the affected corneal layer: epithelial and subepithelial dystrophies, Bowman's membrane dystrophies, and endothelial dystrophies. Each of these conditions exhibits a unique set of clinical features, variable patterns of inheritance, a distinct age of onset, and varying rates of progression. Corneal dystrophies can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner [106]. Various corneal dystrophies are caused by mutations in the CHST6 and KRT genes, KRT3 and KRT12, PIP5K3, SLC4A11, TACSTD2, TGFBI, and UBIAD1 [107]. Mutations in three genes are known to cause posterior polymorphic corneal dystrophy: OVOL2, ZEB1, and GRHL [108]. Some of the most common diseases of this group are Fuchs' corneal endothelial dystrophy (FECD) and keratoconus, which will be described in this section.

[12] Exosomes and autophagy in ocular surface and retinal diseases: new insights into pathophysiology and treatment

  • Authors: Shisi Ma, Xiao Liu, Jiayang Yin, Lili Hao, Yuyao Diao et al.
  • Year: 2022
  • Venue: Stem Cell Research & Therapy
  • URL: https://www.semanticscholar.org/paper/0b2f71753b36ab64128e70e6ec7e092664090601
  • DOI: 10.1186/s13287-022-02854-8
  • PMID: 35505403
  • PMCID: 9066793
  • Citations: 14
  • Summary: The relationship between exosomes and autophagy is mostly focused on fundus diseases, while a deeper understanding of them will provide new directions for the pathological mechanism, diagnosis, and treatment of ocular surface and retinal diseases.
  • Evidence snippets:
  • Snippet 1 (score: 0.612) > Corneal dystrophy (CD) with the abnormal deposition of substances in the cornea, is sub-classified by the anatomic location affected: epithelial/subepithelial, epithelial-stromal, stromal, and endothelial dystrophies [77]. Corneal endothelial cells are attached to the descemet membrane, results in vision impairment and corneal edema when damage or loss [78,79]. Previous study indicates that mesenchymal stem cell-derived extracellular vesicles down-regulate the endoplasmic reticulum stressrelated genes, up-regulate the Akt pathway to inhibit the levels of apoptosis related caspase-3 activation in human corneal endothelial cells in vitro model, suggesting a potential therapeutic effect on corneal endothelial dystrophy [80]. > Fuchs endothelial corneal dystrophy (FECD) is the most common corneal endothelial dystrophy, which is a genetically complex, heterogenous, age-related degenerative disease of corneal endothelial cells with a higher incidence in females. The activation of PINK1-Parkinmediated mitophagy could degrade mitochondrial quality control proteins in FECD [81]. Lattice corneal dystrophy (LCD) is a degenerative disorder that causes loss of corneal transparency and eventually leads to loss of vision, and the reversion of the defective autophagic process in macrophages might be a therapeutic strategy for patients. The impairment of autophagic degradation of mutant transforming growth factor-β-induced protein (Mu TGFBIp) as a result of incomplete autophagy flux in macrophages, which prevented the further phagocytic activation and lead to LCD [82]. Thiel-Behnke corneal dystrophy (TBCD) caused by mutations of TGFB is an epithelial-stromal dystrophy and will be treated by the activation of autophagic flux and the amelioration of lysosomal function [83].

[13] Methylation in cornea and corneal diseases: a systematic review

  • Authors: Yutong Xia, Kuangqi Chen, Qianjie Yang, Zhitong Chen, Le Jin et al.
  • Year: 2024
  • Venue: Cell Death Discovery
  • URL: https://www.semanticscholar.org/paper/b662dc58df9e68e05829396ae03dbc2a4cb98ed3
  • DOI: 10.1038/s41420-024-01935-2
  • PMID: 38589350
  • PMCID: 11002037
  • Citations: 11
  • Summary: The major alterations of methylation and demethylation at the DNA, RNA, and protein levels in corneal diseases and how these dynamics contribute to the pathogenesis of corneal diseases are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.607) > Corneal dystrophies are rare genetic disorders that impact both eyes. They occur due to the accumulation of specific substances produced in various layers of the cornea. There are different classifications of corneal dystrophies depending on anatomical structure, clinical manifestations, and inherence patterns [183,184]. Currently, methylation studies on corneal dystrophies are mainly conducted in Fuchs endothelial cell dystrophy (FECD), with a few in Granular corneal dystrophy type 2 (GCD2) [185][186][187]. > The most prevalent corneal endothelial dystrophy, FECD, is a significant indicator and the leading cause of corneal transplant surgeries among patients worldwide [188,189]. FECD is a highly prevalent, progressively bilateral disease [190]. Generally, the gradual and persistent loss and dysfunction of endothelial cells in both structures and function eventually result in corneal edema [142,191]. The corneal endothelial cells (CEnCs) are derived from the neural crest and are in a specialized extracellular mesenchyme. Many diseases that impact CEnCs can compromise corneal function and visual acuity. Therefore, it is crucial to maintain a specific physiological range of stromal hydration for clear vision [192]. FECD is linked to several spontaneous and inherited mutations, characterized by abnormal accumulation of extracellular mesenchyme, but the underlying molecular pathogenesis of it is unknown [187,193]. DNA methylation has recently been suggested to affect corneal endothelial metabolism, cytoskeletal structure, and ion transport [186]. Some investigators have speculated that DNA methylation patterns may contribute to corneal edema and the resulting loss of corneal transparency in FECD [12]. Besides, miRNA gene promoters are often affected by abnormal DNA methylation in FECD. miRNAs, which are tiny noncoding RNAs that have undergone extensive evolutionary conservation, regulate not only fundamental biological processes including development, stress, and metabolism but also the entire course of disease development [194,195]. The extracellular matrix (ECM) inducible genes snail and ZEB1 are highly expressed in FECD [119].

[14] The application of high-throughput sequencing technology in corneal diseases

  • Authors: Jing Zhao, Yu xi He, Meiliang Wu, Rui Wang
  • Year: 2024
  • Venue: International Ophthalmology
  • URL: https://www.semanticscholar.org/paper/9b03ca82ba8d22d7ae326bab2ab4d8956aa5b636
  • DOI: 10.1007/s10792-024-03049-1
  • PMID: 38340174
  • PMCID: 10858842
  • Citations: 2
  • Summary: The application progress of high-throughput sequencing technology in corneal diseases is introduced, which will help to understand the application of this technology in various corneal diseases.
  • Evidence snippets:
  • Snippet 1 (score: 0.606) > Corneal dystrophy is a progressive keratopathy that is primarily inherited within families. Abnormal genes regulate cells in normal corneal tissue, leading to gradual damage to the structure and function of the cornea. According to the location of the disease, it can be divided into the following three categories: (1) Anterior corneal dystrophy, involving the epithelium and Bowman membrane; (2) Stromal corneal dystrophy involving the stroma or central layer of the cornea; (3) Posterior corneal dystrophy involving Descemet membranes and endodermis. Corneal dystrophy is typically inherited in an autosomal pattern. Due to the specific pathogenic gene and chromosome localization of different subtypes, patients with the same gene mutation may exhibit varying clinical manifestations (Table 2). > At present, the clinical diagnosis of corneal dystrophy needs to be combined with a detailed eye examination, including the examination of the anterior chamber Angle, lens and posterior segment of the eye. Imaging techniques, such as photography, red reflection photographs, optical coherence tomography, mirror microscopy, and living corneal confocal microscopy can be used to provide a comprehensive view of the condition [26]. > However, a definitive diagnosis requires genetic testing. High-throughput sequencing was performed on genes associated with corneal dystrophy to screen out mutant genes, supplemented by molecular karyotype analysis in order to clarify the typing and genetic pattern, and thus achieve precise treatment. Riazuddin et al. [27] used high-throughput sequencing technology to carry out whole gene scanning and found that missense mutation C.2969 g > C in AGBL1. This mutation affects the encoding of AGBL1, a cytoplasmic glutamate decarboxylase, and reduces its interaction with TCF4. The authors suggest that TCF4 may be an enzymatic target of AGBL1 and this interaction could potentially explain development of Fuchs endothelial corneal dystrophy (FECD). Zhang et al. [28] performed TRIa-based whole exome sequencing on a patient with congenital hereditary endothelial dystrophy (CHED) and their parents.

[15] Emerging Innovations in the Treatment of Fuchs Endothelial Corneal Dystrophy: A Narrative Review

  • Authors: Magdalena Niestrata, James Jackson, Shehnaz Bazeer, M. Gong, Zahra Ashena
  • Year: 2025
  • Venue: Medical Sciences
  • URL: https://www.semanticscholar.org/paper/95d19820ef24391851b19ca62c2e8cab4a4ae2d4
  • DOI: 10.3390/medsci13040238
  • PMID: 41283239
  • PMCID: 12642020
  • Summary: This narrative review summarises current and emerging therapeutic strategies for FECD and outlines future directions that are likely to combine advanced surgical techniques with cell-based and biomaterial solutions to deliver accessible, long-term restoration of vision for patients with FECD.
  • Evidence snippets:
  • Snippet 1 (score: 0.600) > Fuchs endothelial corneal dystrophy (FECD) is a degenerative eye disorder characterised by the progressive loss of endothelial cells in the cornea, which are crucial for maintaining corneal clarity by regulating fluid balance. As these cells deteriorate, fluid accumulates within the cornea, resulting in corneal oedema, clouding, and subsequent vision loss. This condition, although genetic, often manifests later in life making it more common in older adults. > Contemporary global meta-analysis estimates that approximately 7.33% of adults over 30 years of age are affected by Fuchs' endothelial corneal dystrophy, with prevalence projected to rise from around 300 million in 2020 to 415 million by 2050 [1]. > Recent research has shed more light on FECD's complex pathophysiology. Notably, the common late-onset form of FECD is associated with a non-coding trinucleotide repeat expansion in the TCF4 gene, leading to toxic RNA aggregates and oxidative stress in endothelial cells [2]. This results in the hallmark formation of guttae (focal collagen excrescences on Descemet's membrane) and accelerates endothelial cell loss. Early-onset familial FECD, in contrast, often stems from missense mutations (e.g., in COL8A2), causing more aggressive endothelial failure [2]. Ultimately, as endothelial pump function declines, corneal hydration increases and oedema worsens, triggering the visual decline observed in FECD. Understanding these disease mechanisms underscores the development of effective treatment modalities. > With the global population ageing, the incidence of FECD is expected to rise, leading to an increase in cases of corneal decompensation, particularly after common procedures like cataract surgery. This decompensation occurs when the already compromised endothelial cells are unable to recover from the stress of surgery, exacerbating the condition and accelerating the need for intervention. > Currently, the gold standard treatment for FECD is Descemet membrane endothelial keratoplasty (DMEK). This advanced surgical procedure involves replacing the diseased endothelial layer with healthy donor tissue.

[16] A family of fuchs endothelial corneal dystrophy and anterior polar cataract with an analysis of whole exome sequencing

  • Authors: Xue Jiang, Xin Jin, N. Zhang, Hong Zhang
  • Year: 2020
  • Venue: Ophthalmic Genetics
  • URL: https://www.semanticscholar.org/paper/81553fa52037540bf35082f7b1423c6ee23a9135
  • DOI: 10.1080/13816810.2020.1759109
  • PMID: 32367751
  • Citations: 2
  • Influential citations: 1
  • Summary: A family of FECD with APC is introduced, with no known causative gene found by WES, inferring that there may be a novel gene-locus in the non-coding regions of genome, which needs further study by WGS.
  • Evidence snippets:
  • Snippet 1 (score: 0.597) > Fuchs endothelial corneal dystrophy (FECD, OMIM:136800) is the most common form of corneal dystrophy, first documented by Ernst Fuchs in 1910 (1). FECD is a bilateral, slowly progressive corneal disease. It is characterized by deterioration of endothelial cells and development of guttae excrescences of Descemet's membrane (1)(2)(3)(4), which may eventually lead to corneal edema and reduced vision (4,5). The pathophysiology of FECD involves several proposed mechanisms involving channelopathies, oxidative stress, apoptosis, and the epithelial-mesenchymal transition. The underlying pathophysiology remains unknown (6,7).The prevalence of FECD in people over 50 years old is 4%-9%, varing by regions (5,6,8). In contrast to Caucasians with much higher FECD prevalence, fewer cases of FECD occur in the Asian population (7). > Age and gender are important factors influencing the development of FECD. People over 40 and female have a higher risk, with a female-to-male ratio of 2.5-3:1 (1,5,6). FECD displays in an autosomal dominant inheritance with incomplete penetrance, about 50% of the patients have a positive family history (6,9). Clinically, FECD can be divided into early-onset FECD and late-onset FECD. Early-onset FECD, which began in the first decade of life, shows similar progress to classic phenotypes. The initial clinical manifestation of late-onset form of FECD (corneal guttae) usually occurs in the fourth decade of life (1,6,10). Usually, patients do not need intervention until the sixth or seventh decades (1,6). > FECD is genetically complex and several genetic variations are known to be related to it (5). Mutations in COL8A2 (OMIM: 120252) is associated with the rare early-onset FECD.

[17] Pathological molecular mechanism of symptomatic late-onset Fuchs endothelial corneal dystrophy by bioinformatic analysis

  • Authors: Zekai Cui, Qiaolang Zeng, Yonglong Guo, Shiwei Liu, Peiyuan Wang et al.
  • Year: 2018
  • Venue: PLoS ONE
  • URL: https://www.semanticscholar.org/paper/701c4f26f1761f8156b9e9d7f991a1310f152a7d
  • DOI: 10.1371/journal.pone.0197750
  • PMID: 29787599
  • PMCID: 5963778
  • Citations: 25
  • Influential citations: 1
  • Summary: It is revealed that down-regulated IL-6, enhanced NF-κB activity and a suite of orchestrated chemokine responses induce fibrocyte differentiation from monocyte to dendritic cell maturation, and PI3K plays a key role in the molecular mechanism of symptomatic late-onset FECD.
  • Evidence snippets:
  • Snippet 1 (score: 0.592) > Fuchs endothelial corneal dystrophy (FECD) is a degenerative disease characterized by corneal endothelial decompensation. FECD causes corneal stromal and epithelial edema and progressively develops into bullous keratopathy, which can eventually lead to blindness. However, the exact pathogenesis is unknown. In this study, we performed an in-depth bioinformatic analysis of the dataset GSE74123 to determine the differentially expressed genes (DEGs) of symptomatic late-onset FECD compared with a normal control. Gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis were used to analyze the pathological molecular mechanism of FECD. We found that cell senescence, reactive oxygen species (ROS), the extracellular matrix (ECM), epithelial-mesenchymal transition (EMT) and immune response-related genes play an important role in the pathological development of symptomatic late-onset FECD. In addition, we revealed that down-regulated IL-6, enhanced NF-κB activity and a suite of orchestrated chemokine responses induce fibrocyte differentiation from monocyte to dendritic cell maturation. PI3K plays a key role in the molecular mechanism of symptomatic late-onset FECD. This study enhances our understanding of the molecular mechanism of FECD pathogenesis and will improve the diagnostics and therapy of FECD patients in the future.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.